John Flavin Contributor More posts by this contributor 2021 should be a banner year for biotech startups that make smart choices early Kevin O’Connor
biotechnology
Cutting out carbon emitters with bioengineering at XTC Global Finals on July 22
Bioengineering may soon provide compelling, low-carbon alternatives in industries where even the best methods produce significant emissions. Utilizing natural and engineered biological process has
This startup just created a fast, accurate COVID test that only needs saliva and links to an app
We’re entering a phase in the COVID-19 pandemic where transmission is going to go through the roof because of the Delta variant. But as
Extra Crunch roundup: Video pitch decks, Didi’s regulatory struggles, Nothing CEO interview
The numbers don’t lie. According to DocSend, the average pitch deck is reviewed for just three minutes. And if you think a senior VC
Biden proposes ARPA-H, a health research agency to ‘end cancer’ modeled after DARPA
In a joint address to Congress last night, President Biden updated the nation on vaccination efforts and outlined his administration’s ambitious goals. Biden’s first
2021 should be a banner year for biotech startups that make smart choices early
Michael B. Gray Contributor Michael B. Gray is partner and leader of the private equity, venture capital and growth companies practice, Neal Gerber Eisenberg.
Bluu Biosciences raises cash to become Europe’s first purveyor of lab grown salmon, trout, and carp
A startup from Europe is joining the race to become the first big provider of lab grown fish. Bluu Biosciences has raised €7 million
Immunai raises $60M as it expands from improving immune therapies to discovering new ones, too
Just three years after its founding, biotech startup Immunai has raised $60 million in Series A funding, bringing its total raised to over $80
FDA clears emergency use of lab-made antibodies to treat COVID-19
The FDA just cleared a medical advance that could play an important (if limited) role in treating COVID-19 patients. The administration has granted emergency
Andreessen Horowitz articles biology biotechnology chemicals dna DNA sequencing Dropbox drug development drug discovery Emerging-Technologies executive Flagship Ventures General Partner genetic engineering genetics george church Ginkgo Bioworks google harvard Jason Kelly jorge conde Pharmaceutical synthetic biology TC
Emerging from stealth, Octant is bringing the tools of synthetic biology to large scale drug discovery
Octant, a company backed by Andreessen Horowitz just now unveiling itself publicly to the world, is using the tools of synthetic biology to buck